Literature DB >> 20191612

Androgen depletion up-regulates cadherin-11 expression in prostate cancer.

Yu-Chen Lee1, Chien-Jui Cheng, Miao Huang, Mehmet A Bilen, Xiangcang Ye, Nora M Navone, Khoi Chu, Hsin-Hsin Kao, Li-Yuan Yu-Lee, Zhengxin Wang, Sue-Hwa Lin.   

Abstract

Men with castration-resistant prostate cancer (PCa) frequently develop metastasis in bone. The reason for this association is unclear. We have previously shown that cadherin-11 (also known as OB-cadherin), a homophilic cell adhesion molecule that mediates osteoblast adhesion, plays a role in the metastasis of PCa to bone. Here, we report that androgen-deprivation therapy up-regulates cadherin-11 expression in PCa. In human PCa specimens, immunohistochemical staining showed that 22/26 (85%) primary PCa tumours from men with castration-resistant PCa expressed cadherin-11. In contrast, only 7/50 (14%) androgen-dependent PCa tumours expressed cadherin-11. In the MDA-PCa-2b xenograft animal model, cadherin-11 was expressed in the recurrent tumours following castration. In the PCa cell lines, there is an inverse correlation between expression of cadherin-11 and androgen receptor (AR), and cadherin-11 is expressed in very low levels or not expressed in AR-positive cell lines, including LNCaP, C4-2B4 and VCaP cells. We showed that AR likely regulates cadherin-11 expression in PCa through an indirect mechanism. Although re-expression of AR in the AR-negative PC3 cells led to the inhibition of cadherin-11 expression, depletion of androgen from the culture medium or down-regulation of AR by RNA interference in the C4-2B4 cells or VCaP cells only produced a modest increase of cadherin-11 expression. Promoter analysis indicated that cadherin-11 promoter does not contain a typical AR-binding element, and AR elicits a modest inhibition of cadherin-11 promoter activity, suggesting that AR does not regulate cadherin-11 expression directly. Together, these results suggest that androgen deprivation up-regulates cadherin-11 expression in prostate cancer, and this may contribute to the metastasis of PCa to bone. Our study suggests that therapeutic strategies that block cadherin-11 expression or function may be considered when applying androgen-ablation therapy. Copyright (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20191612      PMCID: PMC2936767          DOI: 10.1002/path.2687

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  VCaP, a cell-based model system of human prostate cancer.

Authors:  S Korenchuk; J E Lehr; L MClean; Y G Lee; S Whitney; R Vessella; D L Lin; K J Pienta
Journal:  In Vivo       Date:  2001 Mar-Apr       Impact factor: 2.155

2.  Cadherin-11 is expressed in invasive breast cancer cell lines.

Authors:  M J Pishvaian; C M Feltes; P Thompson; M J Bussemakers; J A Schalken; S W Byers
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

3.  Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.

Authors:  T T Wu; R A Sikes; Q Cui; G N Thalmann; C Kao; C F Murphy; H Yang; H E Zhau; G Balian; L W Chung
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

Review 4.  Biology and clinical management of prostate cancer bone metastasis.

Authors:  Xiang-cang Ye; Michel Choueiri; Shi-Ming Tu; Sue-Hwa Lin
Journal:  Front Biosci       Date:  2007-05-01

Review 5.  Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.

Authors:  Eli Rosenbaum; Michael A Carducci
Journal:  Expert Opin Pharmacother       Date:  2003-06       Impact factor: 3.889

6.  Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector.

Authors:  Cristina B B Lira; Khoi Chu; Yu-Chen Lee; Mickey C-T Hu; Sue-Hwa Lin
Journal:  Protein Expr Purif       Date:  2008-06-27       Impact factor: 1.650

7.  The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.

Authors:  B J Furr; H Tucker
Journal:  Urology       Date:  1996-01       Impact factor: 2.649

8.  Cell- and gene-specific regulation of primary target genes by the androgen receptor.

Authors:  Eric C Bolton; Alex Y So; Christina Chaivorapol; Christopher M Haqq; Hao Li; Keith R Yamamoto
Journal:  Genes Dev       Date:  2007-08-15       Impact factor: 11.361

9.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.

Authors:  C A Pettaway; S Pathak; G Greene; E Ramirez; M R Wilson; J J Killion; I J Fidler
Journal:  Clin Cancer Res       Date:  1996-09       Impact factor: 12.531

10.  Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.

Authors:  Chien-Jui Cheng; Xiang-cang Ye; Funda Vakar-Lopez; Jeri Kim; Shi-Ming Tu; Dung-Tsa Chen; Nora M Navone; Li-Yuan Yu-Lee; Sue-Hwa Lin; Mickey C-T Hu
Journal:  Mol Cancer Res       Date:  2007-07       Impact factor: 5.852

View more
  21 in total

1.  Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Authors:  Ziyue Karen Jiang; Makoto Sato; Liu H Wei; Chinghai Kao; Lily Wu
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

Review 2.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

3.  Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases.

Authors:  Tianhong Pan; Eliza L S Fong; Mariane Martinez; Daniel A Harrington; Sue-Hwa Lin; Mary C Farach-Carson; Robert L Satcher
Journal:  Cancer Lett       Date:  2015-05-21       Impact factor: 8.679

4.  Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells.

Authors:  Robert L Satcher; Tianhong Pan; Mehmet A Bilen; Xiaoxia Li; Yu-Chen Lee; Angelica Ortiz; Andrew P Kowalczyk; Li-Yuan Yu-Lee; Sue-Hwa Lin
Journal:  J Cell Sci       Date:  2015-10-30       Impact factor: 5.285

5.  Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts.

Authors:  Chih-Fen Huang; Cristina Lira; Khoi Chu; Mehmet Asim Bilen; Yu-Chen Lee; Xiangcang Ye; Soo Mi Kim; Angelica Ortiz; Fe-Lin Lin Wu; Christopher J Logothetis; Li-Yuan Yu-Lee; Sue-Hwa Lin
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

6.  Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.

Authors:  Benjamin M Johnson; Bently P Doonan; Faisal F Radwan; Azizul Haque
Journal:  Open Prost Cancer J       Date:  2010-01-01

7.  Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone.

Authors:  Mihoko Hatano; Yoshihiro Matsumoto; Jun-Ichi Fukushi; Tomoya Matsunobu; Makoto Endo; Seiji Okada; Kunio Iura; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Yuko Fujiwara; Akira Nabeshima; Nobuhiko Yokoyama; Suguru Fukushima; Yoshinao Oda; Yukihide Iwamoto
Journal:  Clin Exp Metastasis       Date:  2015-06-20       Impact factor: 5.150

8.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

Review 9.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03

10.  Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Authors:  Tzu-Hua Lin; Soo Ok Lee; Yuanjie Niu; Defeng Xu; Liang Liang; Lei Li; Shauh-Der Yeh; Naohiro Fujimoto; Shuyuan Yeh; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-05-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.